Jaguar Health, Inc. 8-K

What Happened
Jaguar Health, Inc. announced two financing transactions on June 9, 2026. The company entered an equity line of credit (ELOC) agreement with an institutional accredited investor committing to purchase up to $40 million of common stock under specified purchase mechanics and limits. Separately, Jaguar closed a private placement issuing 240 shares of newly created Series P Non‑Convertible Preferred Stock for an aggregate $2 million. The company filed a Certificate of Designation for the Series P on June 8, 2026.

Key Details

• ELOC: Institutional investor committed to buy up to $40,000,000 of common stock; ELOC Floor Price initially $1.10/share (adjustable for splits/reorgs). Company may use Fixed Purchases (single fixed purchase cap $1,500,000), VWAP Purchases and Additional VWAP Purchases with daily dollar/volume limits and a 4.99% beneficial‑ownership cap for the investor. Company issued $800,000 of common stock (Commitment Shares) to the investor on effectiveness of the ELOC registration statement. Stockholder approval for the ELOC was obtained at the reconvened 2026 Annual Meeting (June 8, 2026).
• Preferred financing: 240 shares of Series P Preferred sold for $2,000,000 (private placement closed June 9, 2026). Certificate authorizes up to 300 Series P shares; Stated Value per preferred share is $10,000 and dividends accrue at 8% per year on the Stated Value, payable quarterly in cash or in common stock (subject to conditions and caps).
• Registration and rights: Jaguar must file Form S‑1 registration statements (within 30 days) to register resale of shares issued under both transactions and related securities; the company agreed to customary registration‑related obligations and indemnities.
• Preferred terms & limits: Series P is non‑convertible, carries a liquidation preference equal to the Stated Value plus accrued dividends, contains mandatory/optional redemption mechanics, transfer/ownership caps (generally 4.99% without consent), and holder remedies/forced redemption triggers (e.g., registration failures, suspension of trading, unpaid dividends, or if preferred remain outstanding after three years). Series P is not expected to be listed.

Why It Matters
These financings provide Jaguar Health with near‑term capital flexibility: the ELOC gives access to up to $40M of committed capital over time, while the $2M preferred sale raises immediate proceeds. However, both transactions can be dilutive: the ELOC contemplates substantial future issuances of common stock (including $800K of commitment shares) and Series P dividends may be paid in common stock, subject to caps and ownership limits. The Series P also carries a liquidation preference and potential forced‑redemption rights that could affect equity holders in certain events. Investors should watch future registration effectiveness, issuance activity under the ELOC, any redemptions/conversions or pre‑funded warrant exercises, and the company’s disclosures about share counts and dilution.